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Cisplatin is one of the most effective anti-tumour agents for the
treatment of a variety of human solid tumours, including testicular,
ovarian, bladder, lung and head and neck cancers (Loehrer and
Einhorn, 1984). The major dose-limiting side-effect of cisplatin
is nephrotoxicity (Colvin, 1993). Pathological studies have
suggested that different portions of the kidney display different
degrees of damage in response to cisplatin in vivo (Blachley and
Hill, 1981; Brady et al, 1990; Leibbrandt et al, 1995). Cisplatin is
taken up by renal tubular cells, reaching its highest concentrations
in the renal tubular cells of the inner cortex and outer medulla,
which includes cells of the proximal tubule and thick ascending
limb of Henle (Blachley and Hill, 1981; Chopra et al, 1982).
However, distal convoluted tubules may also be involved in
cisplatin-induced kidney injury (Gonzales-Vitale et al, 1977;
Chopra et al, 1982).
Despite two decades of clinical use as a chemotherapeutic drug,
the mechanisms by which cisplatin causes kidney damage and
different degrees of damage within different portions of the kidney
are not well understood. The development of in vitro culture of
immortalized but non-transformed renal tubular epithelial cells
provides a model to address these problems. Our approach was
based upon studies by Brinster and colleagues suggesting the
feasibility of creating immortalized cell culture lines from trans-
genic mice expressing certain portions of the early SV40 virus
DNA (Palmiter et al, 1985). We dissected specific portions of the
nephron of a Brinster large T transgenic mouse and cultured the
segments separately on collagen-coated wells. This resulted in the
production of a unique set of immortalized but non-transformed
renal tubular epithelial cell culture lines: the cell lines S1 and S3,
derived from early and late portions of the proximal tubule,
respectively, and DCT cells, derived from the distal convoluted
tubule. The cultured cells display contact inhibition as well as
characteristics similar to those observed in corresponding freshly
dissected nephron segments. For example, S1 and S3 cells are
gluconeogenic, produce increased amounts of ammonia in
response to acid challenge and respond appropriately to hormones.
DCT cells display parathyroid hormone sensitivity (Nagami et al,
1990, 1991, 1992; Kaunitz et al, 1993).
In this study, we show that cisplatin and carboplatin affect these
cell lines differentially in a fashion that is similar to in vivo data.
Cisplatin and carboplatin cytotoxicity and uptake differ among the
three cell lines. We show that the rate of transport of cisplatin is
not a determinant of the differential sensitivity among renal cells.
Also, for the first time, we present data that suggest that there is a
saturable component of cisplatin uptake. In all cell types, apop-
tosis occurs in cisplatin-induced cell death.
MATERIALS AND METHODS
Cell culture
S1, S3 and DCT cell lines were established as described previously
(Kaunitz et al, 1993). S1cells were derived from the earliest proximal
tubule segment, S3 cells from the late straight proximal tubule and
DCT cells from the early distal convoluted tubule from a large T-
antigen transgenic mouse. Cells were grown in cell culture dishes or
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USAmultiwell plates in Dulbecco’s modified Eagle medium
(DMEM)–Ham’s F12 medium (Sigma) supplemented with 7%
heat-inactivated fetal bovine serum, 5 m ml–1 insulin and 5 ng ml–1
sodium selenite at 37°C in 5% carbon dioxide/35% oxygen. All cell
lines tested negative for mycoplasma contamination.
Cytotoxicity assay
Confluent monolayers were treated with various concentrations
of cisplatin (Sigma) and carboplatin (Bristol-Myers Squibb,
Princeton, NJ, USA) for 2 h and washed and replenished with
DMEM-Ham’s F12 medium. Cytotoxicity for all studies was
assayed 48 h later by incubating the cells with 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as previ-
ously described (Kaunitz et al, 1993). The 48 h time point was
chosen to mimic the clinical situation, as the first signs of cisplatin
nephrotoxicity become apparent after 48 h in vivo through
increased serum creatinine levels. Briefly, the cell monolayers
were incubated for 3 h with MTT at a final concentration of
1 mg ml–1 in the culture medium and then extracted with 100%
2-propanol. MTT incorporation and metabolism to formazan dye
is a measure of cell viability. The concentration of formazan dye
was determined spectrophotometrically at 570 nm. The corre-
sponding IC50 (drug concentration at 50% growth inhibition) was
calculated by linear regression of the resulting logarithmic–linear
dose–response curves.
Cellular accumulation of platinum
For each data point, three confluent 100-mm dishes were exposed
to various concentrations of cisplatin or carboplatin for various
time periods up to 1 h. For high cisplatin concentrations, crys-
talline cisplatin obtained from Sigma was weighed out and trans-
ferred directly into an appropriate volume of medium. Cisplatin
dissolved with vigorous shaking at 37°C within 30 min. The
uptake rate of both drugs was linear over a 1-h time range, as
shown in Figure 5. After incubation, cell monolayers were rinsed
once with ice-cold phosphate-buffered saline (PBS), then
trypsinized, detached by gentle shaking, transferred to a test tube
and centrifuged for 3 min at 2000 g at 4°C. The pellet was resus-
pended in 300 ml of PBS and an aliquot of 30 ml was taken for
protein determination. After recentrifugation for 3 min at 2000 g,
the pellet was digested with 270 ml of 65% nitric acid overnight
and assayed for elemental platinum content by atomic absorption
spectroscopy (Parti and Wolf, 1990). The molar amount of
elemental platinum is equivalent to the molar amount of incorpo-
rated cisplatin or carboplatin. The instrument settings for a Perkin
Elmer 2380 atomic absorption spectrophotometer with attached
HGA-2100 controller were selected as follows: drying tempera-
ture, 75°C; drying time, 50 s; charring temperature, 1800°C; char-
ring time, 40 s; atomizing temperature, 2700°C; atomizing time,
6 s; absorption, 265.9 nm; sensitivity, ± 0.3 mM platinum in
sample; detection minimum, 0.2 mM platinum in sample.
Extraction and electrophoresis of DNA
Cells were treated with 50 mM cisplatin for 2 h, then washed and
replenished with complete medium. After 48 h, cells were
harvested, washed twice with PBS and lysed in 10 mM Tris-HCl
(pH 7.5), 100 mM EDTA, 0.5% sodium dodecyl sulphate (SDS)
and 100 mg ml–1 proteinase K for 18 h at 37°C. DNA was extracted
twice with phenol–chloroform–isoamyl alcohol (25:24:1) (PCI)
and recovered in the aqueous phase. DNA was precipitated with
ethanol, centrifuged for 30 min at 10 000 g, and incubated in
TE buffer [10 mM Tris-HCl (pH 8), 1 mM EDTA] containing
100 mg ml–1 RNAase for at least 1 h at 37°C. DNA was extracted
one more time in PCI and precipitated in 70% ethanol. It was then
resuspended in TE buffer and 10-mg DNA samples were elec-
trophoresed on a 1% agarose gel for 2 h at 45 V. Negatives of
Polaroid pictures of the gel were scanned with an AMBIS optical
imaging system per video camera and, using AMBIS QuantProbe
software, the areas of cleaved vs uncleaved DNA were quantified
densitometrically.
DAPI staining of nuclear DNA
The fluorescent dye DAPI (4¢,6-diamidine-2¢-phenylindole di-
hydrochloride, Boehringer Mannheim Biochemical) stains nuclear
DNA so that condensation and division of chromatin can be readily
detected. Cells were grown to subconfluence on coverslips and
exposed to 50 mM cisplatin for 2 h. After washing and refeeding with
fresh medium, cells were incubated for an additional 48 h. They were
then incubated with DAPI–methanol (1 mg ml–1) for 15 min at 37°C.
Cells were washed once with methanol and then air dried on the
coverslip. Apoptotic cells were easily identified and the per cent
apoptosis was determined by examination of at least 300 nuclei.
Pictures were taken with an inverted microscope–camera apparatus
with a 340-nm excitation filter and a 400-nm barrier filter at a magni-
fication of ´ 400.
Western blot analysis
Following trypsinization of confluent cell layers, cells were
washed in cold PBS and lysed for 10 min on ice in 10 ml of lysis
buffer [1% Triton-X 100 (Sigma), 0.5% NP40, 10 mM Tris,
pH 7.4, 150 mM sodium chloride, 1 mM EDTA, 1 mM EGTA,
0.4 mM sodium vanadate, 0.2 mM sodium fluoride, 0.4 mM phenyl-
methylsulphonyl fluoride, 1.4 mg ml–1 pepstatin, 25 mM p-nitro-
phenyl phosphate]. Lysates were cleared at 14 000 r.p.m. in a
microcentrifuge for 15 min at 4°C. Protein (30 mg) from each
sample was boiled for 5 min in loading buffer (50 mM Tris, pH 6.8,
2% SDS, 10% glycerol, 0.1% bromophenol blue, 1% b-mercap-
toethanol). Proteins were separated by 12.5% SDS-polyacry-
lamide gel electrophoresis and transferred onto PVDF membranes
(Bio-Rad Trans-Blot Transfer Medium). The membranes were
blocked for 1 h at room temperature in 3% bovine serum albumin,
5% non-fat dried milk in TBS buffer (10 mM Tris pH 7.5, 100 mM
sodium chloride, 0.2% Tween 20). After four washes in TBS, the
membranes were incubated with 0.5 mg ml–1 rabbit anti-mouse
BCL-2, BCL-X and BAX antibodies (kind gift of Dr John Reed,
La Jolla, CA, USA) for 1 h. After six more washes, the membranes
were exposed to 1 mg ml–1 horseradish peroxidase (HRP)-labelled
goat anti-rabbit IgG antibody (Amersham, Arlington Heights, IL,
USA) and the bands of the BCL family proteins were detected
with an ECL system.
Statistics
For cytotoxicity studies, the data were based on at least three inde-
pendent experiments for a five point dose–response curve in tripli-
cate. The IC50 values for each cell line were determined by linear
regression of the corresponding logarithmic–linear dose–response
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IC50 values were calculated using standard single-variable statis-
tics. Variability is expressed in means and standard deviations.
Data of each treatment group were subject to a one-way analysis
of variance. Group comparisons were done with a Student–
Newman–Keuls test with significance taken at P < 0.05.
RESULTS
Platinum toxicity in renal tubule epithelial cells
To determine drug cytotoxicity, confluent renal tubule epithelial
(RTE) cell layers were exposed to increasing concentrations of
cisplatin or carboplatin for 2 h and then washed. Monolayers were
refed with fresh medium and 48 h later an MTT assay was
performed. Figure 1 shows the differential sensitivity of S1, S3 and
DCT cell lines to cisplatin and carboplatin. The IC50 values for
cisplatin were 9.07 ± 0.6 mM for S1 cells, 15.5 ± 4.5 mM for S3 cells
and 16.7 ± 2 mM for DCT cells. The IC50 for S1 cells was signifi-
cantly lower (P= 0.035) than that of the S3and DCT cell lines. Thus,
S1 cells were approximately 1.8-fold more sensitive to cisplatin than
S3 and DCT cells. All three cell lines were much less sensitive to
carboplatin. The corresponding IC50 values for carboplatin were 390
± 150 mM for S1 cells, 730 ± 200 mM for S3 cells and 2940 ± 600 mM
for DCT cells. Again, the S1 cells were the most sensitive to carbo-
platin (P < 0.05). However, DCT cells were distinctly more resistant
to carboplatin than were S3 cells (P < 0.05).
Platinum drug uptake studies
The comparative uptake studies were performed with a concentra-
tion of 100 mM for all compounds. A cisplatin concentration of
100 mM was chosen because it resulted in significant cytotoxicity
at 48 h and because it approximated urinary cisplatin concentra-
tions that are associated with nephrotoxicity (Guo, 1992). Urinary
platinum may significantly contribute to nephrotoxicity because of
a reabsorption of cisplatin into the nephron (see also Discussion).
Figure 2 shows the time course of cisplatin and carboplatin uptake
in DCT, S1 and S3 cells. Platinum uptake in all three cell lines was
linear for up to 1 h. After a 1-h exposure to 100 mM cisplatin, S1, S3
and DCT cells took up cisplatin at different rates: S1 cells accumu-
lated 4.73 ± 0.2, S3 cells 6.8 ± 0.2 and DCT cells 2.65 ± 0.2 pmol
h–1 mg–1 protein (P < 0.05). Thus, each cell line displayed distinct
differences in the rates of cisplatin accumulation. The relative
differences in the rates of accumulation did not correlate with rela-
tive differences in cisplatin cytotoxicity among the cell lines. For
example, S1 cells were found to be most sensitive to cisplatin-
induced cytotoxicity whereas S3 cells accumulated cisplatin at the
highest rate.
Carboplatin was taken up at a significantly slower rate than
cisplatin. After a 1-h exposure the carboplatin levels were 1.66 ±
0.03 in S1 cells, 1.35 ± 0.01 in S3 cells and 0.51 ± 0.03 pmol h–1
mg–1 protein in DCT cells (P < 0.05). The rates of carboplatin accu-
mulation were three- to fivefold lower than the corresponding rates
of cisplatin accumulation but could not fully account for the 43-
to 176-fold lower cytotoxicity of carboplatin compared with
cisplatin. The rates of uptake of carboplatin roughly correlated
with carboplatin cytotoxicity in the three cell lines such that S1
cells, which proved to be the most sensitive to carboplatin, also
accumulated it at the highest rate, whereas DCT cells were the
most resistant to carboplatin and accumulated it at the lowest rate.
The uptake rate was studied as a function of cisplatin concentra-
tion, and the results are shown in Figure 3. Uptake studies by other
investigators cited herein (Binks and Dobrota, 1990; Mann et al,
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Figure 1 IC50 values for cisplatin (n n) and carboplatin ( ) on DCT, S1 and
S3 cells (IC50, dose level resulting in 50% inhibition of cell survival). Confluent
cell monolayers were treated with a range of platinum concentrations for 2 h.
Survival was determined by MTT assay after 48 h. The IC50 values were
determined by linear regression of the corresponding log-linear
dose–response curves
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Figure 2 Time course of cisplatin and carboplatin uptake in DCT, S1 and S3
cells. Confluent cell monolayers were exposed to 100 mM platinum for various
periods. The elemental platinum content was measured by flameless atomic
absorption spectroscopy and correlated with the protein content of the
samples
Figure 3 Uptake of cisplatin as a function of concentration in DCT (s), S1
(n) and S3 (l) cells. Confluent cell monolayers were exposed to various
platinum concentrations up to 8 mM for 1 h. The elemental platinum content
was measured by flameless atomic absorption spectroscopy and correlated
with the protein content of the samples
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n1990), were based on the assumption that the solubility limit of
cisplatin is 3.33 mM (1 mg ml–1), the concentration used by
Bristol-Myers Squibb for infusible cisplatin preparations.
However, solubility of cisplatin is cited in the Merck Index with
2.53 mg ml–1 in water at 25°C, which corresponds to 8.43 mM. A
plot of uptake rate as a function of concentrations up to 8 mM
revealed a saturable component to cisplatin uptake. S1 and DCT
cells showed a non-linear rate vs concentration curve, suggesting
that a saturable uptake mechanism may be involved. S3 cells also
showed a slightly curved line, however saturation was less clear in
this cell line. As it has long been hypothesized that cisplatin uptake
occurs through simple diffusion as well as through a gated channel
(Binks and Dobrota, 1990), we applied a non-linear regression
program to the data. With this curve-fit model, the resulting curve
approximating Michaelis–Menten kinetics explained 99% of the
experimental data. The three cell types showed distinct differences
in their mechanism of uptake in terms of the apparent Vmax and KM
for transport. The S3 cells, which consistently displayed the
highest uptake rate, had an apparent Vmax of 770 pmol h–1 mg–1
protein and an apparent KM of 38 mM, suggesting a high-capacity,
low-affinity transport mechanism. The DCT cells had an apparent
Vmax of 250 pmol h–1 mg–1 protein and an apparent KM of 11 mM,
and S1 cells had an apparent Vmax of 180 pmol h–1 mg–1 protein and
an apparent KM of 8 mM. The lower apparent KM and Vmax values
for DCT and S1 cells in comparison with S3 cells suggest a lower
capacity but higher affinity transport process.
Presence of apoptosis and expression of BCL family
proteins
The role of apoptosis in cisplatin-induced cell death was assessed
after treating confluent cell monolayers with 50 mM cisplatin for
2 h. DNA fragmentation and cellular–nuclear morphology were
assessed 48 h later. Gel electrophoresis of isolated DNA (Figure 4)
demonstrated the formation of endonucleosomal DNA fragmenta-
tion in all three cell lines 48 h after cisplatin treatment.
Densitometric analysis demonstrated 79 ± 7% fragmented DNA in
S1 cells, 76 ± 6% fragmentation in S3 cells and 81 ± 9% fragmen-
tation in DCT cells. Figure 5 shows morphological changes in
DAPI-stained nuclei of S3 cells after cisplatin treatment. The
nuclei of the two other cell lines displayed similar characteristics
(not shown). Compared with the control group of non-treated cells
(left), the nuclei of the treated group were smaller and the
chromatin was segregated into hypercondensed domains, which
assumed a sharply defined spherical or crescentic shape in some
cells (right, see arrows). For 50 mM cisplatin treatment for 2 h,
assayed after 48 h, the count of at least 300 apoptotic vs non-apop-
totic nuclei revealed the following proportion of apoptotic nuclei:
42 ± 7% for S1, 28 ± 5% for S3 and 37 ± 9% for DCT cells.
To investigate the expression pattern of BCL family proteins,
protein extracts of S1, S3 and DCT cells were assayed by Western
blot analysis. All three cell lines expressed very low amounts of
BCL-2 protein relative to BAX protein (Figure 6), with S3 cells
expressing slightly more than the other cell lines. However, the
most marked difference was seen in BCL-X expression, with S1
cells expressing considerably less protein than either S3 or DCT
cells (15% vs S3 and DCT cells by densitometry). In contrast,
BCL-X expression was considerably lower in S1 cells than in S3
and DCT cells. BCL-X immunoblotting detected a 31-kDa molec-
ular weight band consistent with the long form of BCL-X, the anti-
apoptotic protein BCL-XL. Although our anti-BCL-X antibody can
also react with the pro-apoptotic short form, BCL-Xs, we did not
detect the expression of BCL-XS in our immunoblots.
DISCUSSION
These results indicate that cytotoxicity and uptake of cisplatin
differ in murine renal tubule epithelial cells derived from different
segments of the nephron. Our model was designed to mimic the
in vivo condition as closely as possible. The available literature
suggested that the majority of cisplatin, administered systemically
at a high dose of 100 mg m–2 over a period of 1 h, is largely cleared
via the kidney within a few hours after administration.
Toxicological studies also suggest that critical effects to the
nephron occur within the first 4 h after administration (Daley-
Yates and McBrien, 1984; Mistry et al, 1989). In addition, in vivo
renal damage can be detected by increased serum creatinine levels
at 48 h. Nephrotoxicity is observed in 70–80% of patients after
cisplatin treatment, when urinary platinum levels rise up to
40 mg ml–1 (133 mM) or plasma platinum levels are greater than
4 mg ml–1 (13 mM) (Guo, 1992). As urinary platinum levels may be
of crucial importance in nephrotoxicity because of reabsorption of
the drug into the nephron, we took 100 mM cisplatin as a reference
point for our studies. By studying confluent renal epithelial cell
monolayers, which mimic the nephron epithelial surface, under-
going a 2-h exposure to cisplatin at clinically relevant urinary
concentrations, we determined the uptake directly following incu-
bation and the degree of cytotoxicity with an MTT assay after
48 h. We believe these conditions resemble those occurring during
acute renal toxicity secondary to cisplatin exposure. In contrast,
our model is not necessarily relevant to chronic platinum-induced
nephrotoxicity, which may be cumulative over time.
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Figure 4 DNA electrophoresis of control cells (lane A) and 48 h after
cisplatin treatment (50 mM cisplatin for 2 h, lane B). From left to right: DCT
cells from the distal convoluted tubule, S1 cells from an early portion of the
proximal tubule and S3 cells from a late portion of the proximal tubulePrevious in vivo work has demonstrated that proximal tubular
segments of the inner cortex and distal convoluted tubular
segments of the nephron are injured by cisplatin (Gonzales-Vitale
et al, 1977; Blachley and Hill, 1981; Chopra et al, 1982). Our cell
line data correlate with the in vivo situation in that S1 cells of the
early proximal tubule were most sensitive to the cisplatin cytotox-
icity, followed by S3 cells of the late proximal tubule and DCT
cells from the distal convoluted tubule.
The differential cytotoxic effects of cisplatin among the three
different cell lines were not due to differential uptake rates.
Although differences in uptake among the S1, S3 and DCT cell
lines were observed, those differences did not correlate with differ-
ences in cytotoxicity. Uptake rates were highest in S3 cells, lowest
in DCT cells and intermediate in S1 cells. Therefore it appeared
that differences in the transport processes among the cell lines
could not explain the observed differential sensitivity to cisplatin.
However, it is still possible that differential uptake in vivo could
play a role in differential cytotoxicity because the distribution of
cisplatin accumulation along the nephron roughly correlates with
areas of damage (Gonzales-Vitale et al, 1977; Blachley and Hill,
1981; Chopra et al, 1982).
Cisplatin causes apoptosis in cancer (Dive and Hickman, 1991)
and kidney cells (Lieberthal et al, 1996). The differential cytotoxi-
city among the three cell lines may be related to different sensitiv-
ities of the cell lines to apoptotic cell death. Our data demonstrate
that cell death from cisplatin occurs through apoptosis in S1, S3 and
DCT cells. A recent in vitro study demonstrated that the mecha-
nism of renal tubule epithelial cell death was determined by the
concentration of cisplatin. A low concentration (8 mM) induced
apoptotic death, whereas a high concentration (800 mM) resulted in
necrosis (Lieberthal et al, 1996). However, renal cells are never
exposed in vivo to such high necrosis-inducing concentrations
(Guo, 1992). Our findings clearly demonstrate that renal cell cyto-
toxicity induced by cisplatin concentrations and exposure times
that resemble the clinical situation is due to the induction of apop-
tosis. Thus, the relative expression of proteins in the BCL family
may regulate cisplatin cytoxicity and may account for the lack of
correlation between the uptake of cisplatin and cytotoxicity
(Miyashita and Reed, 1992; Minn et al, 1995). Although we
assessed the expression of only three proteins in this rapidly
expanding family, it was interesting that S1 cells, which had an
increased sensitivity to the cytotoxic effect of cisplatin, had a rela-
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Figure 5 DAPI staining of S3 control cells (A) and 48 h after cisplatin treatment (50 mM cisplatin for 2 h, B). Arrows indicate condensed chromatin. S1 and DCT
cell lines displayed very similar characteristics. Pictures were taken at a magnification of ´ 400tively reduced expression in the anti-apoptotic BCL-XL protein.
The reduced expression of the anti-apoptotic BCL-XL protein may
have a greater impact on apoptosis than the reduction of the anti-
apoptotic BCL-2 protein (Simonian et al, 1997). This may explain
the similar cytotoxic effects of cisplatin in S3 and DCT cells
despite reduced expression of BCL-2 in DCT cells compared with
S3 cells.
Although differences in uptake rates of cisplatin did not explain
the differential cytotoxicities observed among the three cell lines,
the differences in uptake characteristics suggest that different
transport mechanisms for cisplatin occur in the different cell lines.
In vivo studies have demonstrated that proximal tubule cells of the
inner cortex and outer medulla and distal convoluted cells accu-
mulate cisplatin (Gonzales-Vitale et al, 1977; Blachley and Hill,
1981; Chopra et al, 1982). Our data in cultured cells correlate with
these in vivo data. Furthermore, the cell culture model allowed a
better quantitative characterization of the cisplatin uptake process
because of the ability to control the concentrations of cisplatin and
the timing of exposure, and to measure accurately cisplatin accu-
mulation in the cultured cells. Until recently, the strongest argu-
ment against a transporter-mediated cisplatin uptake mechanism
was that cisplatin uptake was not saturable. Previous uptake
studies were performed at lower cisplatin concentrations because
of the assumption that the solubility limit of cisplatin in saline was
3.3 mM (Binks and Dobrota, 1990; Mann et al, 1990). Our experi-
ments demonstrated solubility at 10 mM at 37°C. Studying the
uptake of cisplatin over a range of concentrations up to 8 mM
allowed us to obtain evidence that a component of cisplatin uptake
was saturable in S1 and DCT cells. Because of the high apparent
KM and the limitations of solubility of cisplatin, it was not possible
to separate completely the saturable from the non-saturable
components of cisplatin uptake. Thus, although the regression
analysis demonstrated that Michaelis–Menten-type kinetics could
largely explain the experimental data, we prefer to refer to the
calculated KM and Vmax values as ‘apparent’ values. Even with
these reservations, the data suggested that the cell lines displayed
differences in uptake mechanisms. The capacity for cisplatin
uptake was higher in S3 cells than in S1 and DCT cells, as was
suggested by higher apparent Vmax values in S3 cells. The similarity
in the apparent KM values observed in S1 and DCT cells suggested
that the affinity for cisplatin was similar in these two cell types,
whereas the higher KM value in S3 cells suggested a reduced
affinity for cisplatin.
It is well known that cisplatin is much more nephrotoxic in vivo
than is carboplatin. In our study, all three renal cell lines were
much more sensitive to cisplatin than to carboplatin, with a 43- to
176-fold difference in sensitivity. This large relative difference in
toxicity in the renal cells contrasted with data on various tumour
cell lines (Knox et al, 1986; Hospers et al, 1988; Schurig et al,
1990; Mellish et al, 1993; Klaushofer et al, 1995) which displayed
only a 5- to 24-fold greater sensitivity to cisplatin compared with
carboplatin. In experiments not presented here, we also compared
the immortalized, non-transformed RTE cell lines with non-renal
control, murine immortalized, non-transformed osteoblasts,
MC3T3 cells (Micetich et al, 1985). MC3T3 cells showed a 20- to
30-fold difference in sensitivity between cisplatin and carboplatin,
i.e. similar to the tumour cells. These data suggest that renal cells
exhibit properties that render them more sensitive to cisplatin, or
less sensitive to carboplatin, when compared with tumour and
other non-renal cells.
The difference in the cytotoxic effects between cisplatin and
carboplatin observed in the three renal cell lines could not entirely
be accounted for by differences in uptake because cisplatin had
only a three- to fivefold higher uptake rate than carboplatin. Thus,
mechanisms other than transport appeared to be involved in the
differential toxicities of cisplatin and carboplatin. One possible
explanation for the different renal cytotoxicities of cisplatin and
carboplatin is that in renal cells cisplatin tends to form more toxic,
reactive intermediates (e.g. aquated compounds) than carboplatin
(Knox et al, 1986; Micetich et al, 1985). Because cisplatin has
demonstrated a higher anti-tumour activity than carboplatin in
most tumour models, the major use of carboplatin has been when
nephrotoxicity is a major risk, such as in high-dose chemotherapy
with bone marrow stem cell rescue. Thus, an understanding of the
differences between these drugs that influence nephrotoxic poten-
tial might help in future studies that attempt to ameliorate cisplatin
side-effects.
In summary, the use of homogeneous cell lines derived from
different portions of the nephron allowed us to detect significant
differences in platinum cytotoxicity and uptake among the cell
lines. These data suggest that future therapeutic interventions to
protect renal tubular epithelial cells from cisplatin toxicity will
have to take into consideration the different sensitivities and trans-
port characteristics displayed by cells from different portions of
the nephron.
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